{'52WeekChange': -0.10739809,
 'SandP52WeekChange': 0.0644362,
 'address1': '409 Illinois Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 42.46,
 'askSize': 1300,
 'averageDailyVolume10Day': 587462,
 'averageVolume': 733312,
 'averageVolume10days': 587462,
 'beta': 1.571988,
 'beta3Year': None,
 'bid': 39.93,
 'bidSize': 800,
 'bookValue': 5.156,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 43.09,
 'dayLow': 41.74,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -33.366,
 'enterpriseToRevenue': 12.969,
 'enterpriseValue': 3334618880,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '415 978 1902',
 'fiftyDayAverage': 41.049713,
 'fiftyTwoWeekHigh': 48.95,
 'fiftyTwoWeekLow': 22.65,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 82602779,
 'forwardEps': -0.96,
 'forwardPE': -44.239586,
 'fromCurrency': None,
 'fullTimeEmployees': 531,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.08270001,
 'heldPercentInstitutions': 0.74702,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/fibrogen.com',
 'longBusinessSummary': 'FibroGen, Inc., a biopharmaceutical company, '
                        'discovers, develops, and commercializes therapeutics '
                        'to treat serious unmet medical needs. It is '
                        'developing Roxadustat, an oral small molecule '
                        'inhibitor of hypoxia inducible factor prolyl '
                        'hydroxylases that is in Phase III clinical '
                        'development for the treatment of anemia in chronic '
                        'kidney disease in the United States and Europe; and '
                        'in Phase II/III development in China for anemia '
                        'associated with myelodysplastic syndromes. The '
                        'company is also developing Pamrevlumab, a human '
                        'monoclonal antibody that inhibits the activity of '
                        'connective tissue growth factor that is in Phase III '
                        'clinical development for the treatment of idiopathic '
                        'pulmonary fibrosis, pancreatic cancer, liver '
                        'fibrosis, and diabetic kidney disease, as well as '
                        'Phase II trial for the treatment of Duchenne muscular '
                        'dystrophy. It has collaboration agreements with '
                        'Astellas Pharma Inc. and AstraZeneca AB. The company '
                        'was incorporated in 1993 and is headquartered in San '
                        'Francisco, California.',
 'longName': 'FibroGen, Inc.',
 'market': 'us_market',
 'marketCap': 3784281088,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28484',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -109907000,
 'nextFiscalYearEnd': 1640908800,
 'open': 42.35,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '415 978 1200',
 'previousClose': 42.88,
 'priceHint': 2,
 'priceToBook': 8.237005,
 'priceToSalesTrailing12Months': 14.718243,
 'profitMargins': -0.42745999,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 43.09,
 'regularMarketDayLow': 41.74,
 'regularMarketOpen': 42.35,
 'regularMarketPreviousClose': 42.88,
 'regularMarketPrice': 42.35,
 'regularMarketVolume': 397312,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 89104800,
 'sharesPercentSharesOut': 0.083900005,
 'sharesShort': 7475264,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6708969,
 'shortName': 'FibroGen, Inc',
 'shortPercentOfFloat': 0.0962,
 'shortRatio': 7.88,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'FGEN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.26,
 'twoHundredDayAverage': 38.90784,
 'volume': 397312,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.fibrogen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94158'}